KymaThera
PrivateLast Round
Series B
Oct 6, 2026
Total Funding Raised
$80M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
KymaThera operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in October 2026.
KymaThera is a biotechnology company that develops precision medicines for genetically defined diseases using a proprietary structure-based drug design platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
KymaThera Comparables
Compare KymaThera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GPCR Therapeutics | 81% | |
| Orion Biotechnology | 81% | |
| Superluminal Medicines | 81% |
For institutional investors. Book with your work email.
KymaThera Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
KymaThera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Foresite Capital | Series B |
| J. Wood Capital Advisors | Series B |
| Venrock | Series B |
| Alta Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 6, 2026
$80M round led by Alta Partners.
- Aug 21, 2026
Monthly visitors grew 57% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 7, 2026
KymaThera is initially developing K-1728, an oral PI3Kα inhibitor, for HR+/HER2- breast cancer and is exploring it for PI3Kα-driven vascular malformations, with Phase 1 dosing expected in Q4 '26.
- receives_financingOct 7, 2026
KymaThera closes an $80M Series B round in California in October 2026, led by Alta Partners with Venrock, Foresite Capital, J. Wood Capital, and other investors participating, to advance K-1728 toward clinical development.
For institutional investors. Book with your work email.
KymaThera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about KymaThera's valuation, stock price, and market status.
Is KymaThera a public or private company?
KymaThera is a private company.
What is the current stock price of KymaThera?
KymaThera is a private company, so its shares have no public market price. Caplight tracks KymaThera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is KymaThera worth (valuation)?
Valuation information for KymaThera is not publicly available.
Can I buy KymaThera stock?
KymaThera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was KymaThera's last funding round?
KymaThera's most recent funding round was Series B on October 6, 2026.
Who are the main investors in KymaThera?
Key investors in KymaThera include Alta Partners.
Will KymaThera IPO soon?
No public IPO plans have been announced for KymaThera.
How can I track KymaThera secondary market activity?
Caplight tracks bids, offers, and trades in KymaThera's shares on secondary markets.